| Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") | 09/25 08:00 | prnewswire.com |
| Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer | 09/03 08:00 | prnewswire.com |
| Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates | 08/06 20:31 | zacks.com |
| Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates | 08/06 19:46 | zacks.com |
| Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance | 08/06 16:05 | prnewswire.com |
| Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 | 07/30 16:05 | prnewswire.com |
| Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System | 07/15 08:00 | prnewswire.com |
| Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know | 07/11 13:02 | zacks.com |
| New Strong Buy Stocks for July 11th | 07/11 08:11 | zacks.com |
| Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") | 07/02 08:00 | prnewswire.com |